Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study Evaluating TRIV-573 in Atopic Dermatitis
Sponsor: Triveni Bio
Summary
The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573. Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo). The study duration for individual participants is up to 40 weeks, including a Screening period of up to 30 days.
Official title: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-573 in Participants With Moderate to Severe Atopic Dermatitis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-09-09
Completion Date
2028-02
Last Updated
2026-10-28
Healthy Volunteers
No
Conditions
Interventions
TRIV-573
TRIV-573 (Subcutaneous injection)
Placebo
Placebo (Matching Placebo subcutaneous injection)
Locations (17)
Triveni Bio Site #15
Fountain Valley, California, United States
Triveni Bio Site #4
Los Angeles, California, United States
Triveni Bio Site #11
Boca Raton, Florida, United States
Triveni Bio Site #7
Miami, Florida, United States
Triveni Bio Site #3
Miami, Florida, United States
Triveni Bio Site #2
Indianapolis, Indiana, United States
Triveni Bio Site #13
Bay City, Michigan, United States
Triveni Bio Site #16
Boardman, Ohio, United States
Triveni Bio Site #1
Camp Hill, Pennsylvania, United States
Triveni Bio Site #14
Myrtle Beach, South Carolina, United States
Triveni Bio Site #9
San Antonio, Texas, United States
Triveni Bio Site #6
San Antonio, Texas, United States
Triveni Bio Site #8
Spokane, Washington, United States
Triveni Bio Site #17
Calgary, Alberta, Canada
Triveni Bio Site #5
Barrie, Ontario, Canada
Triveni Bio Site #12
Ivano-Frankivsk, Ukraine
Triveni Bio Site #10
Kyiv, Ukraine